# Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer

> **NCT07653451** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 90 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Afatinib + Toripalimab
- **DRUG:** Dalpiciclib + Pyrotinib
- **DRUG:** Camrelizumab + Apatinib

## Key facts

- **NCT ID:** NCT07653451
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07653451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07653451, "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07653451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*